2018 年第 5 期 第 13 卷

苯磺酸左旋氨氯地平联合降压益肾颗粒对原发性高血压患者的临床疗效观察

Effect of levamlodipine besylate combined with Jiangya Yishen granules on primary hypertension

作者：魏景美马玉花

英文作者：

单位：810000西宁，青海省心脑血管病专科医院高血压科

英文单位：

关键词：原发性高血压；苯磺酸左旋氨氯地平；降压益肾颗粒；血小板衍生生长因子BB；抵抗素

英文关键词：

• 摘要：

• 目的    探讨苯磺酸左旋氨氯地平联合降压益肾颗粒对原发性高血压患者的临床疗效。方法    选取青海省心脑血管病专科医院2015年11月至2017年4月收治的原发性高血压患者98例，应用随机数字表法分为2组，各49例。2组患者均接受戒烟、限酒、运动指导及饮食控制等常规干预，对照组给予苯磺酸左旋氨氯地平口服，观察组在对照组治疗基础上联合降压益肾颗粒治疗。比较2组患者治疗前后血压和血清血小板衍生生长因子BB（PDGF-BB）、抵抗素水平以及健康调查简表（SF-36）评分的变化，根据治疗后血压改善情况评估疗效，记录治疗过程中的不良反应。结果    治疗后，2组患者的收缩压和舒张压均较治疗前降低，且观察组低于对照组［(127±12)mmHg(1 mmHg=0.133 kPa)比（140±12）mmHg，（68±10）mmHg比（76±11）mmHg］，差异均有统计学意义（均P＜0.05）。治疗后,2组患者的血清抵抗素均较治疗前降低，观察组PDGF-BB低于治疗前，且观察组PDGF-BB及抵抗素水平低于对照组［(18±7)μg/L比（23±10）μg/L，(0.25±0.11)mmol/L比（0.48±0.15）mmol/L］，差异均有统计学意义（均P＜0.05）。治疗后，对照组和观察组SF-36评分均高于治疗前［(76±6)分比（64±6）分，(85±6)分比（65±5）分］，且观察组高于对照组，差异均有统计学意义（均P＜0.001）。治疗2个月后观察组的总有效率高于对照组［91.8%(45/49)比71.4%(35/49）］，差异有统计学意义（χ2=6.806，P=0.009）。2组患者不良反应发生率比较差异无统计学意义（P＞0.05）。结论    苯磺酸左旋氨氯地平与降压益肾颗粒联合治疗，可降低原发性高血压患者血压及血清PDGF-BB、抵抗素水平，提高疗效，改善患者生活质量，且具有安全性。

• 【Abstract】Objective    To investigate the clinical effect of levamlodipine besylate combined with Jiangya Yishen granules on primary hypertension. Methods    A total of 98 patients with primary hypertension admitted from November 2015 to April 2017 in Qinghai Province Cardiovascular and Cerebrovascular Disease Hospital were randomly divided into control group and observation group（n＝49）. The control group took levamlodipine besylate tablets; the observation group took levamlodipine besylate tablets and Jiangya Yishen granules. Changes of blood pressure, levels of serum platelet derived growth factor-BB（PDGF-BB） and resistin, quality of life(SF-36) score and adverse reactions were analyzed. Results    Before treatment, systolic pressure and diagnostic pressure had no significant differences between groups（P＞0.05）. After treatment, systolic pressure and diagnostic pressure decreased compared to those before treatment and there were significant differences between observation group and control group［(127±12)mmHg vs （140±12）mmHg， （68±10）mmHg vs （76±11）mmHg］（P＜0.05）. Before treatment, levels of serum PDGF-BB and resistin had no significant differences between groups（P＞0.05）. After treatment, resistin level significantly decreased in both groups and PDGF-BB level significantly decreased in observation group（P＜0.05）; levels of serum PDGF-BB and resistin in observation group were significantly lower than those in control group［(18±7)μg/L vs （23±10）μg/L， (0.25±0.11)mmol/L vs （0.48±0.15）mmol/L］（P＜0.05）. After treatment, SF-36 scores in both observation and control groups significantly increased compared to those before treatment［(76±6) vs （64±6）， (85±6) vs （65±5）］; SF-36 score in observation group was significantly higher than that in control group（P＜0.001）. The total effective rate in observation group was significantly higher than that in control group［91.8%(45/49) vs 71.4%(35/49）］（χ2=6.806， P=0.009）. The incidence rate of adverse reactions showed no significant difference between groups（P＞0.05）. Conclusion    Levamlodipine besylate combined with Jiangya Yishen granules treating primary hypertension can effectively reduce blood pressure, serum levels of PDGF-BB and resistin, improve therapeutic effect and quality of life.

  【Key words】Primary hypertension;Levamlodipine besylate;Jiangya Yishen granules;Platelet derived growth factor-BB;Resistin